Actively Recruiting
Phase 3 Study of AD-227A and AD-227B Combination Treatment for Adults with Essential Hypertension
Led by Addpharma Inc. · Updated on 2025-02-04
251
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining two drugs, AD-227A and AD-227B, in adults with essential hypertension. This Phase III randomized, double-blind study aims to understand how well this combination works to control blood pressure compared to other treatments. The trial is sponsored by Addpharma Inc. and focuses on patients diagnosed with essential hypertension. Participants will be randomly assigned to one of three groups the combination of AD-227A and AD-227B with a placebo for AD-227C, AD-227A alone with placebos for AD-227B and AD-227C, or the combination of AD-227A and AD-227C. All medications are taken orally once a day as tablets for eight weeks. The study involves careful administration and monitoring of these treatments during this period. During the study, participants will have their blood pressure monitored, with the primary outcome focusing on the change in mean systolic blood pressure from baseline to Week 8. Researchers will conduct regular assessments throughout the eight-week treatment to evaluate safety and effectiveness. The total participation time aligns with this treatment period, during which safety and response to the drugs will be closely observed.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
Research Team
J
JeongEun Park
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here